Abstract. This document updates and expands the initial Infectious Diseases Society of America (IDSA) Fever and Neutropenia Guideline that. Risk of febrile neutropenia (FN) should be systematically assessed (in consultation with infectious disease specialists as needed), including. Febrile neutropenia (FN) is a serious complication of cancer chemotherapy that The Infectious Diseases Society of America (IDSA), National.

Author: Zolorn Fenrisida
Country: Malta
Language: English (Spanish)
Genre: Music
Published (Last): 7 April 2008
Pages: 134
PDF File Size: 17.1 Mb
ePub File Size: 19.69 Mb
ISBN: 406-7-66002-484-3
Downloads: 40345
Price: Free* [*Free Regsitration Required]
Uploader: JoJolar

Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: However, fluconazole lacks anti-mold coverage; its prophylactic efficacy in the HSCT population can be attributed to prevention of invasive candidiasis [ ]. Additional information is available at www. Compendia Alternative Payment Ffbrile. Urinalysis and sputum and stool cultures may be necessary in patients with suspected infection in the associated sites.

Empirical treatment of C. Rather, the recommendations outlined in these guidelines are generally applicable in most clinical situations but, in some instances, will require modifications according to circumstances and local epidemiologic data. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. Empirical antifungal coverage should be considered in high-risk patients who have persistent fever after 4—7 days of a broad-spectrum antibacterial regimen and no identified fever source A-II.

In the absence of effector cells, primarily neutrophils, signs and symptoms of inflammation may be lacking and rapid progression of invasive bacterial infections may occur, so antibiotics are a life-saving measure in this situation. Vancomycin-resistant Tebrile aureus in the absence of vancomycin exposure. An IV-to-oral switch in antibiotic idsq may be made if patients are clinically stable and gastrointestinal absorption is felt to be adequate A-I. This antifungal prophylactic benefit has not been established for post-remission consolidation therapy for acute leukemia and is not routinely recommended.

Members of the Panel completed the IDSA conflict of interest disclosure statement and were asked to identify ties to companies developing products neutropenai might be affected by promulgation of the guideline. Addition of a gram-positive active agent to fluoroquinolone prophylaxis is generally not recommended A-I.


Rather, the aim is to cover the most likely and most virulent pathogens that may rapidly cause serious or life-threatening infections in a given patient. In addition, earlier detection of invasive fungal infections has led to debate regarding optimal use of empirical or preemptive antifungal therapy, although algorithms are still evolving.

Hemodynamically unstable neutropenic patients with persistent fever without a clear source should have their antimicrobial regimen broadened to ensure adequate coverage for drug-resistant gram-negative and gram-positive organisms, as well as for anaerobes.

Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital.

Treatment of febrile neutropenic patients with cancer who require hospitalization: Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: They are not intended to supplant physician judgment with respect to particular patients or special clinical situations.

Because allogeneic HSCT recipients are at risk for invasive molds as well as for Candida infections, it stands to reason that broader-spectrum antifungal agents, such as late-generation azoles, would neutroppenia more effective prophylaxis. Daily assessments include laboratory tests and cultures for infection, fever trends, and toxicity of treatment.

Antimicrobial modifications should be based on identified or suspected pathogens if none can be cultured and neutropenla available antimicrobial susceptibility data, including local susceptibility and resistance trends.

IDSA GUIDELINES Bundle (free trial)

Public Health Patient Stories. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. In low-risk patients without documented infection, continuing antibiotic therapy until resolution of both fever and neutropenia is the standard approach.

The Panel recommends that either the clinical judgment criteria that have been based upon data derived from published clinical trials or the MASCC assessment tool can be used to stratify risk for patients presenting with fever and neutropenia. Vancomycin is not a standard part of empirical antibiotic therapy for fever and neutropenia.

What has not changed is the indication for immediate empirical antibiotic therapy. Comparison of meropenem with amikacin plus ceftazidime in the neutropsnia treatment of febrile neutropenia: In a preliminary analysis, each group had a similar rate of fungal infection and fungal-free survival, although there was a trend toward fewer Aspergillus infections among patients receiving voriconazole.

Carefully selected febrile adult neutropenic patients at low risk for complications during neutropenia may be treated initially with neutrooenia broad-spectrum antibiotics [ 222—3442—4345]. Sputum samples for routine bacterial culture should be sent if the patient has a productive cough.


Guidelines in the Management of Febrile Neutropenia for Clinical Practice

CT of other areas head, sinuses, abdomen, and pelvis should be performed as clinically indicated. If an exposure to influenza occurs, 5 days of post-exposure treatment with anti-influenza antivirals eg, oseltamivir or zanamivir is recommended for the neutropenic patient regardless of vaccination status [ ].

Allogeneic HSCT recipients and patients undergoing induction therapy for acute leukemia are the primary constituents of this high-risk group.

It updates the IDSA document that was last revised in [ 1 ]. In various studies of prospective serial serum galactomannan testing in high-risk patients, sensitivity has ranged widely among different patient populations and has depended upon the optical density cutoff used to define a positive test [ — ]. For the update, the Panel completed the review and analysis of data neutropsnia since In the initial multivariate analysis that led to the development of the MASCC criteria, longer neutropenia duration was not found to be a significant risk factor for poor outcome [ 43 ].

Detection of bloodstream infections in adults: The primary aim of the practice guideline is to assist practitioners in making decisions about appropriate nuetropenia for neutropenic patients who present with signs and symptoms of potentially serious infections [ 18 ].


Guidelines in the Management of Febrile Neutropenia for Clinical Practice

Many experts recommend this approach for high-risk patients []. Cookies facilitate the functioning of this site including a member login and personalized experience. Hand hygiene, maximal sterile barrier precautions, and cutaneous antisepsis with chlorhexidine during CVC vebrile are recommended for all CVC insertions A- – I.

Initiation of inadequate or limited regimens for health care—associated pneumonia is a major risk factor for excess mortality and prolonged length of stay [ ]. Once antibiotic therapy has been started, DTP might not be idza.